Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sutro Biopharma (STRO) Interest & Investment Income (2017 - 2025)

Sutro Biopharma's Interest & Investment Income history spans 9 years, with the latest figure at -$737000.0 for Q3 2025.

  • For Q3 2025, Interest & Investment Income fell 104.17% year-over-year to -$737000.0; the TTM value through Sep 2025 reached -$11.1 million, down 198.28%, while the annual FY2024 figure was $18.6 million, 266.75% up from the prior year.
  • Interest & Investment Income for Q3 2025 was -$737000.0 at Sutro Biopharma, up from -$1.0 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $17.7 million in Q3 2024 and bottomed at -$15.4 million in Q4 2023.
  • The 5-year median for Interest & Investment Income is $109000.0 (2021), against an average of $247789.5.
  • The largest annual shift saw Interest & Investment Income crashed 2657.8% in 2022 before it soared 2106.9% in 2023.
  • A 5-year view of Interest & Investment Income shows it stood at -$3.6 million in 2021, then skyrocketed by 307.13% to $7.5 million in 2022, then tumbled by 305.16% to -$15.4 million in 2023, then surged by 47.71% to -$8.0 million in 2024, then surged by 90.83% to -$737000.0 in 2025.
  • Per Business Quant, the three most recent readings for STRO's Interest & Investment Income are -$737000.0 (Q3 2025), -$1.0 million (Q2 2025), and -$1.3 million (Q1 2025).